Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Molina

Showing results (501-510 of 647) with videos related to

Pageof 65
Sort By:
Journal of Hazardous Materials|November 20, 2019
Contamination of N-poor wastewater with emerging pollutants does not affect the performance of purple phototrophic bacteria and the subsequent resource recovery potentialI de Las Heras, R Molina, Y Segura, et al.
Anticancer Research|September 2, 1999
C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patientsR Molina, J Jo, X Filella, et al.
Revista Medica De Chile|February 14, 2014
[Prevalence of Gilbert syndrome and its genetic determinants in Chile]Luis Méndez, Marcela Lagoa, Teresa Quiroga, et al.
British Journal of Cancer|October 1, 1996
Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3R Molina, J Jo, G Zanón, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 3, 2010
Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancerRebecca Suk Heist, Jerry Fain, Bernard Chinnasami, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|December 5, 2003
Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factorsR Molina, X Filella, J M Augé, et al.
Archivos Espanoles De Urologia|May 24, 2012
Impossible bladder catheter removal. What can we do?R Molina Escudero, F Herranz Amo, E Lledo Garcia, et al.
Environment International|February 7, 2012
Drugs of abuse in surface and tap waters of the Tagus River basin: heterogeneous photo-Fenton process is effective in their degradationY Valcárcel, F Martínez, S González-Alonso, et al.
Human Pathology|September 10, 2019
Loss of ATRX expression predicts worse prognosis in pulmonary carcinoid tumorsSimone B S P Terra Md, Hao Xie Md PhD, Jennifer M Boland Md, et al.
Investigational New Drugs|April 25, 2020
A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumorsMojun Zhu, Julian R Molina, Grace K Dy, et al.
Pageof 65

Showing results (501-510 of 647) with videos related to

Sort By:
Pageof 65
Journal of Hazardous Materials|November 20, 2019
Contamination of N-poor wastewater with emerging pollutants does not affect the performance of purple phototrophic bacteria and the subsequent resource recovery potentialI de Las Heras, R Molina, Y Segura, et al.
Anticancer Research|September 2, 1999
C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patientsR Molina, J Jo, X Filella, et al.
Revista Medica De Chile|February 14, 2014
[Prevalence of Gilbert syndrome and its genetic determinants in Chile]Luis Méndez, Marcela Lagoa, Teresa Quiroga, et al.
British Journal of Cancer|October 1, 1996
Utility of C-erbB-2 in tissue and in serum in the early diagnosis of recurrence in breast cancer patients: comparison with carcinoembryonic antigen and CA 15.3R Molina, J Jo, G Zanón, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 3, 2010
Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancerRebecca Suk Heist, Jerry Fain, Bernard Chinnasami, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|December 5, 2003
Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factorsR Molina, X Filella, J M Augé, et al.
Archivos Espanoles De Urologia|May 24, 2012
Impossible bladder catheter removal. What can we do?R Molina Escudero, F Herranz Amo, E Lledo Garcia, et al.
Environment International|February 7, 2012
Drugs of abuse in surface and tap waters of the Tagus River basin: heterogeneous photo-Fenton process is effective in their degradationY Valcárcel, F Martínez, S González-Alonso, et al.
Human Pathology|September 10, 2019
Loss of ATRX expression predicts worse prognosis in pulmonary carcinoid tumorsSimone B S P Terra Md, Hao Xie Md PhD, Jennifer M Boland Md, et al.
Investigational New Drugs|April 25, 2020
A phase I study of the VEGFR kinase inhibitor vatalanib in combination with the mTOR inhibitor, everolimus, in patients with advanced solid tumorsMojun Zhu, Julian R Molina, Grace K Dy, et al.
Pageof 65